Quatrx Pharmaceuticals Co Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Ann Arbor MI United States (2000)
Status: Acquired by Shionogi (2017)

Organization Overview

First Clinical Trial
2004
NCT00373516
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

QuatRx

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: Quatrx Pharmaceuticals Co (0) Acquired (1)

ospemifene (osphena) (6 trials)

Drugs in Phase 2 Trials (2)

Key: Quatrx Pharmaceuticals Co (1) Acquired (1)

becocalcidiol (1 trial)

fispemifene (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 3)

Erectile Dysfunction (Phase 2)

Hypogonadism (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Psoriasis (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Vaginal Diseases (Phase 3)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 3